NCT03722329View on ClinicalTrials.gov

Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

November 13, 2018

Primary Completion Date

March 29, 2019

Study Completion Date

April 8, 2019

Conditions

Healthy

Interventions

DRUG

Eculizumab

Eculizumab Injection. 300 mg, single dose

Trial Locations (1)

14050

PAREXEL International GmbH, Early Phase Clinical Unit - Berlin, Berlin

All Listed Sponsors

lead

Samsung Bioepis Co., Ltd.

INDUSTRY

NCT03722329 - Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy Subjects | Biotech Hunter | Biotech Hunter